Aug 20, 2026, 11:37 AMEarnings
Walmart Shares Slide as U.S. Comparable Sales Growth Slows to 2.6%
Walmart shares slid after second-quarter comparable U.S. sales grew 2.6%, their weakest pace in over six years, with falling drug prices weighing on sales.
Listen to this briefingAudio briefing
Summary
MarketWatch reported on August 20, 2026, that Walmart’s second-quarter comparable U.S. sales grew 2.6%, the company’s weakest increase in more than six years. Falling drug prices weighed on U.S. sales, and Walmart shares declined following the report.
Only a short feed summary was available, so the source provided no figures for revenue, earnings, margins, e-commerce, guidance, or the stock’s percentage decline.
Positives
- Comparable U.S. sales increased 2.6% in Walmart’s second quarter.
- U.S. comparable sales remained positive despite pressure from falling drug prices.
- Walmart continued to generate U.S. same-store growth, although the available feed disclosed no additional operating results.
Risks & concerns
- The 2.6% comparable U.S. sales increase was Walmart’s weakest growth in more than six years.
- Falling drug prices reduced Walmart’s reported U.S. sales growth.
- Walmart shares declined after the second-quarter earnings report.
- The limited feed omitted revenue, profit, margin, guidance, and share-price figures, restricting assessment of the quarter.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/walmart-shares-slide-as-u-s-sales-hit-by-falling-drug-prices-1e308c61?mod=mw_rss_topstories
Read full article
